A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Acquisition, Management and Analysis of Biospecimens for The Tumor neo-Epitope Selection Alliance (TESLA)

Type of Cancer
Unknown

Sponsor
Parker Institute

Protocol Number
TESLA

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Phase II study of front line therap